AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 153 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.71 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,341,621,000 | +103.7% | 38,944 | -1.2% | 0.00% | – |
| Q2 2020 | $658,475,000 | +17.8% | 39,406 | +1.6% | 0.00% | – |
| Q1 2020 | $559,150,000 | -59.0% | 38,776 | -4.8% | 0.00% | -100.0% |
| Q4 2019 | $1,362,899,000 | +55.4% | 40,720 | -2.8% | 0.00% | 0.0% |
| Q3 2019 | $877,113,000 | +2.6% | 41,887 | +2.1% | 0.00% | 0.0% |
| Q2 2019 | $854,536,000 | +56.9% | 41,044 | +68.4% | 0.00% | – |
| Q1 2019 | $544,714,000 | +9.0% | 24,372 | +16.6% | 0.00% | – |
| Q4 2018 | $499,928,000 | -12.3% | 20,900 | 0.0% | 0.00% | – |
| Q3 2018 | $570,152,000 | +1.5% | 20,900 | 0.0% | 0.00% | – |
| Q2 2018 | $562,001,000 | -21.0% | 20,900 | -6.5% | 0.00% | -100.0% |
| Q1 2018 | $711,306,000 | +111.3% | 22,347 | +151.1% | 0.00% | – |
| Q4 2017 | $336,598,000 | -95.3% | 8,900 | -96.9% | 0.00% | -100.0% |
| Q3 2017 | $7,214,460,000 | – | 291,023 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 3,300,797 | $90,046,000 | 33.32% |
| Aisling Capital LLC | 1,990,000 | $54,287,000 | 11.73% |
| Foresite Capital Management III, LLC | 801,240 | $21,858,000 | 4.82% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 189,857 | $5,181,000 | 4.12% |
| AlpInvest Partners B.V. | 38,943 | $1,062,000 | 2.27% |
| Eventide Asset Management | 1,739,000 | $47,440,000 | 1.74% |
| Palo Alto Investors LP | 1,381,759 | $37,694,000 | 1.52% |
| Sofinnova Investments, Inc. | 222,295 | $6,064,000 | 0.54% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 553,000 | $15,086,000 | 0.54% |
| EMERALD ADVISERS, LLC | 486,666 | $13,276,000 | 0.49% |